The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Notice for elexacaftor, tezacaftor and ivacaftor (Vertex Pharmaceuticals Australia Pty Ltd)
Active ingredients
elexacaftor, tezacaftor and ivacaftor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Film-coated tablet
Indication
For the treatment of cystic fibrosis in patients who have at least one F508del mutation in the CFTR gene
Therapeutic area
Respiratory